{"page_content": "ALLOGENE ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT    |  4\n4\nfoundational \nplatform \ntechnologies130+\npatients treated with  \nAlloCAR T\u2122 products\n4\nclinical trials \ncurrently \nunderway13\npre-clinical \ntargets\nAlloCAR T\u2122 PRODUCTS:  \nIMPROVING ACCESS TO CELL THERAPY\nAs a leader in the field, we have faced and expect to face complex \nchallenges associated with extending the potential of allogeneic cell \ntherapy  . We take pride in taking the lead, expanding boundaries, building \npartnerships and revolutionizing the future of cancer immunotherapy \nin order to bring new hope to millions of patients suffering from cancer \naround the world  .100+\npatients that may be  \ntreated from\na single  \nmanufacturing run\n", "metadata": {"source": "NASDAQ_ALLO_2022.pdf", "page": 5, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}